How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents.

Bailey, C; Dalziel, K; Cronin, P; Devlin, N; Viney, R; Quality Of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA) Project Team,

How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents.

Bailey, C Dalziel, K Cronin, P

Devlin, N Viney, R

Quality Of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA) Project Team,

Permalink

Publisher:: Springer Science and Business Media LLC
Publication Type:: Journal Article
Citation:: Pharmacoeconomics, 2021
Issue Date:: 2021-11-05

Closed Access

	Filename	Description	Size
	Bailey2021_Article_HowAreChild-SpecificUtilityIns.pdf		1.06 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Bailey, C
dc.contributor.author	Dalziel, K
dc.contributor.author	Cronin, P https://orcid.org/0000-0003-4422-7760
dc.contributor.author	Devlin, N
dc.contributor.author	Viney, R https://orcid.org/0000-0002-0039-9635
dc.contributor.author	Quality Of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA) Project Team,
dc.date.accessioned	2021-11-09T04:42:31Z
dc.date.available	2021-10-13
dc.date.available	2021-11-09T04:42:31Z
dc.date.issued	2021-11-05
dc.identifier.citation	Pharmacoeconomics, 2021
dc.identifier.issn	1170-7690
dc.identifier.issn	1179-2027
dc.identifier.uri	http://hdl.handle.net/10453/151443
dc.description.abstract	Measuring and valuing health-related quality of life (HRQOL) in children can be challenging but is an important component for providing decision makers with accurate information to fund new interventions, including medicines and vaccines for public subsidy. We review funding submissions of medicines made to the Pharmaceutical Benefits Advisory Committee contained in public summary documents to examine the use of child-specific HRQOL measures in decision making in Australia. A sample frame of medicines used by children was derived from four sources. Public summary documents relating to these medicines were searched in the Pharmaceutical Benefits Advisory Committee web resources for whether they related to children (aged under 18 years) and contained HRQOL information and/or cost-utility analyses. Data about the use of utilities in decision making were extracted and analysed. Of the 1889 public summary documents available, 62 public summary documents (29 medicines) contained information pertaining to children and utilities. Of these, four public summary documents included child-specific HRQOL measures, 16 included adult HRQOL measures, 11 included direct elicitation and the HRQOL source was not defined in 31 documents. Excluding documents using child-specific HRQOL measures, we considered that in 85% of medicines, decision making uncertainty might have been reduced by using child-specific HRQOL measures. Despite the growing literature on economic analysis in paediatric populations, the use of child-specific HRQOL measures in submissions to the Pharmaceutical Benefits Advisory Committee was minimal. Submissions involved inconsistent approaches, use of adult measures and weights, and substantial gaps in evidence. We recommend the consistent use of child-specific measures to improve the evidence base for decisions about medicines for children in Australia.
dc.language	eng
dc.publisher	Springer Science and Business Media LLC
dc.relation.ispartof	Pharmacoeconomics
dc.relation.isbasedon	10.1007/s40273-021-01107-5
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences, 14 Economics
dc.subject.classification	Health Policy & Services
dc.title	How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents.
dc.type	Journal Article
utslib.location.activity	New Zealand
utslib.for	11 Medical and Health Sciences
utslib.for	14 Economics
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
utslib.copyright.status	closed_access	*
dc.date.updated	2021-11-09T04:42:30Z
pubs.publication-status	Published online

Abstract:

Measuring and valuing health-related quality of life (HRQOL) in children can be challenging but is an important component for providing decision makers with accurate information to fund new interventions, including medicines and vaccines for public subsidy. We review funding submissions of medicines made to the Pharmaceutical Benefits Advisory Committee contained in public summary documents to examine the use of child-specific HRQOL measures in decision making in Australia. A sample frame of medicines used by children was derived from four sources. Public summary documents relating to these medicines were searched in the Pharmaceutical Benefits Advisory Committee web resources for whether they related to children (aged under 18 years) and contained HRQOL information and/or cost-utility analyses. Data about the use of utilities in decision making were extracted and analysed. Of the 1889 public summary documents available, 62 public summary documents (29 medicines) contained information pertaining to children and utilities. Of these, four public summary documents included child-specific HRQOL measures, 16 included adult HRQOL measures, 11 included direct elicitation and the HRQOL source was not defined in 31 documents. Excluding documents using child-specific HRQOL measures, we considered that in 85% of medicines, decision making uncertainty might have been reduced by using child-specific HRQOL measures. Despite the growing literature on economic analysis in paediatric populations, the use of child-specific HRQOL measures in submissions to the Pharmaceutical Benefits Advisory Committee was minimal. Submissions involved inconsistent approaches, use of adult measures and weights, and substantial gaps in evidence. We recommend the consistent use of child-specific measures to improve the evidence base for decisions about medicines for children in Australia.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/151443